ODA-570

ODA-570 is a preclinical-stage **prophylactic mRNA vaccine** developed for the prevention of **malaria**. It is designed and developed by Ocean Biomedical Holdings, with preclinical data suggesting it may eliminate up to 90% of malaria parasites in laboratory models. The vaccine is part of a broader infectious disease pipeline that includes humanized monoclonal antibodies and small molecules targeting malaria. The active ingredient and sequence are based on novel malaria antigens identified by company scientists, but the precise antigenic targets and mRNA payload composition are not publicly disclosed. Current evidence supporting ODA-570’s efficacy is limited to animal and laboratory studies; no human data are reported yet[3][4][5].